Our Mission
Monopar Therapeutics strives to develop proprietary therapeutics designed to extend life or improve the quality of life for cancer patients
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive® (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.
Monopar's team is located in San Francisco, CA and Chicago, IL.
Licensing, developing and commercializing transformative oncology therapeutics
Multiple factors drive our passion for oncology
The numbers behind our research define Validive and camsirubicin opportunities
Validive® (clonidine MBT), a Phase 3-ready mucoadhesive buccal tablet for the prevention and treatment of chemoradiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 2 clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; and MNPR-101 (formerly huATN-658), a pre-IND stage humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid cancers.
Product | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
Validive® |
Radiation induced SOM in OPC |
Preclinical complete |
Phase 1 complete |
Phase 2 in progress |
Phase 3 not started |
Phase 2b/3 VOICE trial ongoing |
Camsirubicin |
Advanced Soft Tissue Sarcoma |
Preclinical complete |
Phase 1 complete |
Phase 2 in progress |
Phase 3 not started |
Completed Phase 2 in Soft Tissue Sarcoma, Collaboration with GEIS for larger Phase 2 |
MNPR-101 |
Severe COVID-19 |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Collaboration with NorthStar for severe COVID-19 |
MNPR-101 |
Advanced Solid Cancers |
Preclinical in progress |
Phase 1 not started |
Phase 2 not started |
Phase 3 not started |
Pre-IND |